GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL
Source: 2017 American Society of Hematology Annual Meeting*

Conference Program

 

Slideset

GIMEMA LAL1811: Phase II Study of Frontline Ponatinib + Steroids in Elderly or Unfit Patients With Ph+ ALL

Ponatinib combined with steroids yielded a 90% complete hematologic response and reasonable tolerability profile at Week 24 in unfit and elderly patients with Philadelphia chromosome–positive ALL.
Format: Microsoft PowerPoint (.ppt)
File size: 225 KB
Date posted: 12/20/2017